The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti‐Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE‐1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP‐transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose‐dependent Aβ reduction in the cerebrospinal fluid. Thus, long‐term, pivotal studies with CNP520 have been initiated in the Generation Program. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides LY2886721, many other candidates have also reached late stages of clinical trials, including atabecestat (Phase 2/3),305 elenbecestat (Phase 3),306 lanabecestat (Phase 2/3)307,308 and umibecestat (Phase 2/3).309 However, all of them have failed to receive final approval to reach the market.”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [309]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Umibecestat (14, CNP520), a fourth-generation BACE1 inhibitor, initially showed good safety and tolerability in early clinical studies.444,445”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [445]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to other BACE-1 inhibitors, CNP520 (umibecestat (labeled as 11, Figure 5)) has been shown to reduce the burden of amyloid-beta plaques in preclinical animals; it is presently undergoing testing phases [157,166,167].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [167]
In the citing paper
“or because of a cognitive worsening in the patients, as in the case of Umibecestat (Neumann et al., 2018)”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Neumann et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“…drugs that target Ab is therefore increasingly focused on treatment during the earlier stages of AD (the newly defined preclinical stage and during the stage of mild cognitive impairment) when the disease-modifying therapy targeting Ab presumably will be of greatest benefit (Selkoe & Hardy, 2016).”
BackgroundOn the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204 · cited 1×
“BACE-1 shares high structural similarity with the catalytic and ligand binding sites of these enzymes; however, we increased selectivity for BACE-1 by exploiting the size differences of remote substrate binding pockets, in particular the extended S3 pocket (Schechter & Berger, 1967).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“BACE-1 is a membrane-bound aspartyl protease required for the processing of the amyloid precursor protein (APP) to form the N-terminus of Ab peptides and the protein-soluble APPb (sAPPb) (Vassar et al, 1999).”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“CNP520 robustly reduces human CSF Ab In humans, determination of the direct BACE-1 product sAPPb and of Ab peptides in CSF allows measurement of the effect of CNP520 on APP processing in the brain (Blennow et al, 2010).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 2×
“Inhibition of BACE-1 is a promising disease-modifying strategy for AD, validated by human genetics (Jonsson et al, 2012).”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · cited 1×
“…with a biomarker signature for ongoing Ab deposition both in the APOE4 non-carrier and in the carrier group, but the proportion was higher in the carrier group, in line with reports documenting an increased risk of early Ab deposition in APOE4 carriers (Jansen et al, 2015; Hollands et al, 2017).”
ResultHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“…enrolls people at risk of developing AD based on age and genotype (presence of the APOE4 gene), we investigated the ability of CNP520 to inhibit Ab40 generation preclinically in the APOE4-TR mouse model, in which the mouse Apoe gene is replaced by the human APOE4 gene (Castellano et al, 2011).”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9316 | 2018 1 of 18 et al, 2018; Honig et al, 2018).”
MethodInfluential
Cited by
Items 101–188 of 188
Feng, L., Wang, G., Song, Q., Feng, X., Su, J., Ji, G., & Li, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01330-3 · Cited by 12
“The safety of the drug was confirmed, but its clinical efficacy has not been established yet (Neumann et al. 2018).”
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 13
Zhang, Z., Li, R., Zhou, Y., Huang, S., Hou, Y., & Pei, G. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04557-y · Cited by 13
“The protein receptors were prepared based on the crystal structure of human BACE1 (PDB ID: 6EQM [30]) and crystal structure of GSK3 (PDB ID: 1Q5K [31]) by Protein Preparation Wizard.”
Dziewa, M., Złotek, M., Herbet, M., & Piątkowska‐Chmiel, I. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01514-0 · Cited by 13
Tripeptides inhibit dual targets AChE and BACE-1: a computational study
Tuan, A., Nguyen, T. H., Quân, P. M., Nguyen, H. T., Long, N. P., Vu, V. V., Phùng, H. T. T., & Ngô, S. T. (2025) · RSC Advances · doi:10.1039/d5ra00709g · Cited by 13
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
Ohno, M. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111475 · Cited by 13
Ugbaja, S. C., Appiah‐Kubi, P., Lawal, M. M., Gumede, N. S., & Kumalo, H. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1869099 · Cited by 12
Tadano, G., Komano, K., Yoshida, S., Suzuki, S., Nakahara, K., Fuchino, K., Fujimoto, K., Matsuoka, E., Yamamoto, T., Asada, N., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01140 · Cited by 11
Vormfelde, S. V., Pezous, N., Lefèvre, G. Y., Kolly, C., Neumann, U., Jordaan, P., Ufer, M., & Legangneux, E. (2020) · Clinical and Translational Science · doi:10.1111/cts.12832 · Cited by 11
“028 μM at multiple 50 mg daily doses in the Generation Program.(11) Assessment of the inhibition of hERG by umibecestat demonstrated an IC50 of 3.”
BackgroundMethodInfluentialSelf-citationThe endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 23
Protein aggregation and biomolecular condensation in hypoxic environments (Review)
Li, C., Hao, B., Yang, H., Wang, K., Fan, L., & Xiao, W. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5357 · Cited by 11
“…(252) and ALZT‑OP1 (253); ii) indirect disruption of the signaling pathway that governs aggregation, and several inhibitors, including cNP520 (254) and JNJ‑54861911 (255), have been created to target β ‑site amyloid precursor protein cleaving enzyme signaling in an Ad model; and iv)…”
BackgroundFragment dissolved molecular dynamics: a systematic and efficient method to locate binding sites
Privat, C., Granadino‐Roldán, J. M., Bonet, J., Belenguer, M. S. T., Pérez, J. J., & Rubio, J. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp05471b · Cited by 12
Obrecht, M., Zurbruegg, S., Accart, N., Lambert, C., Doelemeyer, A., Ledermann, B., & Beckmann, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1177421 · Cited by 13
“In view of safety, ARIA-H has become an integral part of animal (Beckmann et al., 2011; Marinescu et al., 2017; Neumann et al., 2018) and clinical studies (Sperling et al.”
BackgroundResultSelf-citationKashyap, K., Panigrahi, L., Ahmed, S., & Siddiqi, M. I. (2023) · Molecular Informatics · doi:10.1002/minf.202200113 · Cited by 10
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
“2 APP processing models without risk of toxicity and severe adverse effects (Neumann et al. 2018).”
Alzheimer’s disease and clinical trials
Paul, D., Agrawal, R., & Singh, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0264 · Cited by 9
Safety concerns associated with BACE1 inhibitors – past, present, and future
Naidu, A., Silverglate, B., Silverglate, M., & Grossberg, G. T. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2467811 · Cited by 8
“Neumann claimed that there were ‘no dose-limiting safety or tolerability findings up to 750-mg single dose, 300 mg for 2 weeks (maximum multiple doses tested), and up to 85 mg for 3 months’ [24].”
Alzheimer’s Disease Pharmacology
Plascencia‐Villa, G., & Perry, G. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00018-9 · Cited by 8
Patwekar, M., Patwekar, F., Khan, S. M., Sharma, R., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266295495240415114919 · Cited by 9
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
McCullough, A. A., Chen, C. D., Gordon, B. A., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R. C., Koudelis, D., McKay, N. S., Hobbs, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70347 · Cited by 9
Toxic mechanisms of amyloid oligomers and therapeutic strategies
Ivanova, M. I., Rosa, C. L., & Ramamoorthy, A. (2026) · Protein Science · doi:10.1002/pro.70519 · Cited by 6
Premkumar, T., & Sajitha Lulu, S. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2335300 · Cited by 7
“PDB ID of the retrieved structure is 6EQM with a resolution of 1.35 Å with no mutation (Neumann et al., 2018).”
InfluentialKengkanna, A., & Ohue, M. (2023) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb56990.2023.10264879 · Cited by 8
Structure-based identification of potent modulators from Centella asiatica targeting BACE-1
Sultana, A., & Woo, J. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42652 · Cited by 7
Khan, A. H., Saeed, A., Gondal, A. B., Hussain, F., Tahir, A., Shah, I., Rashid, U., & Hassan, A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118144 · Cited by 5
Alshehri, Z. S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.08.055 · Cited by 7
Dermawan, D., & Alotaiq, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412143 · Cited by 7
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 7
Morgan, D., & Lamb, B. T. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13566 · Cited by 4
Toledano, J. V., Bello, M., Correa‐Basurto, J., González, I. G., Pacheco‐Yépez, J., & Rosales‐Hernández, M. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00669 · Cited by 5
Rombouts, F. J. R., Hsiao, C., Bache, S., Cleyn, M. A. J. D., Heckmann, P., Leenaerts, J., Martínez‐Lamenca, C., Brandt, S. V., Peschiulli, A., Vos, A. M., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114028 · Cited by 5
da Conceição, R. A., Barbosa, M. L. D. C., & de Souza, A. M. T. (2025) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-025-00712-2 · Cited by 5
Huang, Y., Chan, H., Khoo, J.-Y., Chan, M.-L., Bender, D. A., Ponnusamy, V. K., Belaidi, A. A., & Ke, L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106104 · Cited by 4
Bartolić, M., & Bosak, A. (2025) · BioFactors · doi:10.1002/biof.70071 · Cited by 5
Li, H., Hua, Q., Cheng, S., Liu, X., Cai, Q., Zhang, J., Peng, T., Li, J., Wang, C., Liang, C., et al. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073311518240416070410 · Cited by 4
Eunice, E., & Prasana, J. C. (2025) · Asian Journal of Chemistry · doi:10.14233/ajchem.2025.33504 · Cited by 4
Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors
Taoka, B. M., Wu, W., Hao, J., Dolmaski, M., Wang, H., Levorse, D. A., Orth, P., Hyde, L. A., Smith, B. E., Michener, M. S., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128463 · Cited by 4
Kaur, B., Kaur, R., Vivesh, V., Rani, S., Bhatti, R., & Singh, P. (2024) · ACS Omega · doi:10.1021/acsomega.3c09069 · Cited by 12
Gao, F., Zhang, M., Wang, Q., Ni, M., Liu, C., Deng, K., Xie, Q., Wang, S., Shi, J., & Shen, Y. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02750-w · Cited by 5
Wu, H., Wan, J., Yuan, J., Xie, M., Nie, Q., Liu, Z., & Cai, S. (2024) · Beverage Plant Research · doi:10.48130/bpr-0024-0019 · Cited by 4
Zondagh, L. S., Malan, S. F., & Joubert, J. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106869 · Cited by 3
Bhansali, P. R., Sonkusare, S. M., Savale, S. S., Wijayasinghe, Y. S., Liao, Y., Sloan, D. C., Chaturbhuj, G. U., & Muntean, B. S. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1642190 · Cited by 3
Alzheimer’s Disease: Treatment of Multi-Factorial Disorders with Multi- Target Approach
Singh, P., Kaur, B., & Vivesh, V. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220701112048 · Cited by 3
Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents
Papavasileiou, K. D., Dondero, F., Melagraki, G., & Afantitis, A. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_3 · Cited by 4
Han, X., & Guo, K. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1412349 · Cited by 4
Saini, M., Rohilla, S., & Kumar, R. (2025) · Current Aging Science · doi:10.2174/0118746098376646250715094707 · Cited by 3
Revealing the binding mechanism of BACE1 inhibitors through molecular dynamics simulations
Zhang, Y., Miao, D., Liu, S., & Hao, X. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2319676 · Cited by 6
“…efficiency with a lower IC50 value (IC50 ¼ 5nM), but it did not enter clinical trials in AD due to hair discoloration observed in mice, which was considered a sign of off-target inhibition of BACE2 occurring at therapeutic doses (Neumann et al., 2018; Rueeger et al., 2021; Veenstra et al., 2018).”
Milisavljević, K. D., & Milanović, Ž. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416525501170 · Cited by 2
Increase of brain Aβ peptides and secretase activity during normal aging in rodent and human
Godoy-Lugo, J. A., Thorwald, M. A., Head, E., Gomm, A., Zhang, C., Tanzi, R. E., & Finch, C. E. (2025) · GeroScience · doi:10.1007/s11357-025-01926-w · Cited by 2
“Hence, clinical interventions to diminish amyloid pools could consider inhibitors of the secretases that produce soluble Aβ peptides [31, 32].”
Recent advances towards BACE1 drug discovery and therapeutics design
Imran, S., Patel, M., Noroozifar, M., & Kerman, K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01095k · Cited by 5
Li, Y., Zhang, Y., Wang, Q., Wu, C. K., Du, G., Zeng, Y., Song, Z., Jiang, X., Jiang, X., Zhuo, R., et al. (2024) · Neurological Research · doi:10.1080/01616412.2024.2325313 · Cited by 2
“In particular, by downregulation of BACE1 and thereby inhibiting the production of Aβ, neurotoxicity and cognitive dysfunction can be significantly ameliorated [5,6].”
BackgroundXia, C., & Ma, Q. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/7135399 · Cited by 3
RetractedTreatment of Canine Cognitive Dysfunction With Novel Butyrylcholinesterase InhibitorPreprint
Pipan, M. Z., Mihevc, S. P., Štrbenc, M., Košak, U., Ilić, I. G., Trontelj, J., Žakelj, S., Gobec, S., Pavlin, D., & Majdič, G. (2020) · Research Square · doi:10.21203/rs.3.rs-118291/v1 · Cited by 2
Neurobiomarkers: Basic Aspects and Their Relevance in Nonclinical Studies
Greiter‐Wilke, A., Beckmann, N., Glaab, W. E., Theil, D. J., & Pardo, I. D. R. (2025) · Toxicologic Pathology · doi:10.1177/01926233251335849 · Cited by 2
Self-citationTreatment options for Alzheimer’s Disease: An overview of the amyloid, tau, and alternate hypotheses
Eroltu, K. (2023) · Journal of High School Science · doi:10.64336/001c.89250 · Cited by 1
Efficacy of Beta-Secretase-1 Enzyme Inhibitors in Alzheimer's Disease
Yousefi, R., Mokarmian, S., & Jamshidi, A. (2023) · Journal of Advanced Pharmacy Research · doi:10.21608/aprh.2023.230890.1234 · Cited by 1
Tschirner, S. K., Zuchero, Y. J. Y., Getz, J. A., Müller, S. A., Nalbach, K., Kennedy, M. E., Lewcock, J. W., & Lichtenthaler, S. F. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101012 · Cited by 1
Chettupalli, A. K., Gupta, N., Bukke, S. P. N., Singh, M. P., & Mandal, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118803 · Cited by 1
The future of dementia prevention and treatment strategies
直行, 里. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.374 · Cited by 1
New Perspectives for Treatment in Alzheimer’s Disease
Loureiro, J. C., Silva, L. F. D. A. L. E., Pais, M. V., & Forlenza, O. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-94383-7_10 · Cited by 1
Magnetic Resonance Imaging in Pharmaceutical Safety Assessment
Hockings, P. D., & Beckmann, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_19-1 · Cited by 1
Self-citationFree-radical reactions in the synthesis of organofluorine compounds
Reddy, V. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813286-9.00003-1
Pharmaceutical applications of organofluorine compounds
Reddy, V. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813286-9.00005-5
Finding Cures for Alzheimer's Disease
Huang, X., & Aslanian, R. G. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch4
Meta-Analysis of Natural vs Pharmaceutical Interventions for Alzheimer's Disease
Vrublevskaya, T. (2021) · San José State University ScholarWorks (San Jose State University) · doi:10.31979/etd.b494-dcd5
Yousefi, R., Mokarmian, R., & jamshidi, A. (2023) · Journal of Advanced Pharmacy Research · doi:10.21608/aprh.2023.219909.1223
Perspectivas atuais da doença de Alzheimer: aspectos patogênicos e terapêuticos
Costa, R. D. L. C., Pereira, M. D. A. M., Santana, L. C., Lima, A. S., de Athayde, L. G. G., de Albuquerque, N. C. F., Nunes, A. M. B., Nunes, A. M. B., Nobre, P. V. C., Neto, A. C. R. V., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n5p1500-1511 · Cited by 3
Magnetic Resonance Imaging in Pharmaceutical Safety Assessment
Hockings, P. D., & Beckmann, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_19
Self-citationUnveiling Alzheimer's: Exploring Biomarkers for Diagnosis and Progression
Silviya, S. H. A., Sunitha, T., Jerlin, C. M. H., Sampath, N., & Thiruselvan, P. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch012
Yukti, Sharma, A., Dhar, S., Ojha, R., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.004
Towards in silico prediction of mutations related to antibiotic resistance
Elisée, E. (2019) · theses.fr (ABES) · doi:10.70675/bd16b908zde01z4a9fz9aa5zad9c5670eb37 · Cited by 1
Boucher, S. (2019) · theses.fr (ABES) · doi:10.70675/ecf9d6cbzada9z4072zaec9zaf47b4208831 · Cited by 1
Zakaria, J. A. D., & Vassar, R. J. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_188
Ugwah-Oguejiofor, C. J., Okechukwu, P. N., Mathias, S. N., Ofokansi, M. N., & Janakiraman, A. K. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49144-3.00007-1
Nguyen, T. H., Nguyen, H. N. T., Pham, M. Q., & Phùng, H. T. T. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11653-9
“In the 6EQM structure, umibecestat exemplifies this logic: its compact pose centers on the catalytic cleft, directing heteroatom-rich functionality toward the dyad while packing hydrophobic moieties against the pocket walls [56, 81].”
Small Molecules as Anti-Alzheimer’s Scaffolds
Hazra, R., Roy, S., Gayen, S., Parui, A., Arshad, A., Roy, N., & Sarkar, A. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010013
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“Among these, Umibecestat, sometimes referred to as CNP520, has demonstrated remarkable safety and effectiveness from the initiation of clinical trials (177, 178).”
BindingDB (2023) · UC San Diego · doi:10.7270/q20p13x7
BindingDB (2023) · UC San Diego · doi:10.7270/q2988c2n
Metadata
- Authors
- Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot‐Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B., Beltz, K., Avrameas, A., Kretz, S., Pezous, N., Rondeau, J., Beckmann, N., Hartmann, A., Vormfelde, S., David, O. J., Galli, B., Ramos, R., Graf, A., & Lopez Lopez, C.
- Affiliations
- Novartis (Switzerland) (CH)
- Corresponding author
- Neumann, Ulf
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2018-09-17
- Volume
- 10
- Issue
- 11
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6220303
- OpenAlex
- W2890206141
- Cited by
- 177
- References
- 65
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 34 · 2023: 20 · 2022: 24 · 2021: 23 · 2020: 23 · 2019: 19 · 2018: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Novartis Pharma AG, Basel, Switzerland
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- BACE1 inhibitors, Alzheimer's disease, amyloid-beta, amyloid hypothesis, disease prevention, early Alzheimer's disease, cerebrospinal fluid amyloid-beta, APP transgenic mice, veterinary toxicology, drug safety, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Brain, Cathepsin D, Cerebral Hemorrhage, Female, Humans, Inflammation, Male, Mice, Inbred C57BL, Mice, Transgenic, Oxazines, Hominidae, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Microglia, Amyloid Precursor Protein Secretases, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.